AB Science has a unique and diversified indication portfolio that includes multiple late-stage programs.
Compound
Indication
Therapeutic area
Preclinical
Phase 1/2
Phase 2b/3
Confirmatory Phase 3
NDA/MAA
Masitinib
AB8939
Neurology
Inflammatory
Oncology
Viral disease
Oncology

*: Positive Phase 2B/3 Results Reported